Efficacy and safety of montelukast in patients with asthma and allergic rhinitis in routine clinical practice: results of a prospective multicenter observational program



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. To evaluate efficacy and safety of montelukast in the treatment of adult patients with asthma, allergic rhinitis or with combination of asthma and allergic rhinitis in routine clinical practice. Methods. The open-label, single-arm, prospective, multicenter observational program. No specific procedures beyond routine clinical practice were performed. Data collection was performed at baseline (at the enrollment in the program) as well as after the end of the prescribed course of treatment with montelukast Actavis, but not more than at 12 weeks of treatment. The study included 545 patients. Criteria for efficacy: the frequency of the daytime and nocturnal symptoms of asthma needs the rescue medications, the number of exacerbations during the last 3 months (hospitalizations, calls for specialized medical care), change of the nasal symptoms score (TNSS). Results. After 12 weeks of therapy, the proportion of patients who maintained daily asthma symptoms, decreased by 3,4 times and amounted to only 22% compared to 75,2% at baseline. Especially significant, 4,3-fold, reduced the number of patients with nocturnal symptoms - from 61,8% to 14,4%. The need to use drugs emergency and restriction of activities associated with asthma symptoms also decreased by 3,6 and 3,2 times, respectively. Conclusion. The use of montelukast Actavis in patients with asthma, AR and a combination of asthma and AR is efficient, safe, and helps to improve the control of asthma symptoms and the AR; the improvement of the general condition of patients, as well as reduction of the percentage of eosinophils in the blood was shown. The drug is well tolerated and is convenient for patients.

Full Text

Restricted Access

About the authors

I V Sidorenko

I.M. Sechenov First Moscow State Medical University

Email: isidorenko55@mail.ru
Department of Clinical Immunology and Allergology

T V Zahargevskaya

I.M. Sechenov First Moscow State Medical University

Department of Clinical Immunology and Allergology

References

  1. Asher M.I. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur. Respir. 1995, v. 8, p. 483-491.
  2. Bauchau V., Durham S.R. Prevalence and rate diagnosis of allergic rhinitis in Europe. Eur. Respir. 2004, v. 24, p. 758-764.
  3. Ильина Н.И. Аллергология в различных регионах России по результатам клинико-эпидемиологических исследований. Автореферат диссертации д-ра мед. наук. М., 1996, 31 с.
  4. Лопатин А.С., Чучуева Н.Д. Эпидемиология аллергического ринита в России и в мире. Рос. Аллергол. Журн. 2013, № 2, с. 3-10.
  5. Ильина Н.И., Хаитов Р.М. Эпидемия аллергии, астмы - в чем причина? Астма. 2001, № 1, с. 35-38.
  6. Шогенова М.С. Исследование распространенности аллергических заболеваний среди взрослого населения Кабардино-Балкарской Республики. Рос. Аллергол. Журн. 2005, № 3, с. 50-54.
  7. Cruz A.A., Popov T., Pawankar R. et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update in collaboration with GA2LEN. Allergy. 207, v. 62, p. 1-4.
  8. Leynaert B., Neukirch F., Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J. of Allergy and Clin. Immunology. 2000, v. 106, p. 201-205.
  9. Емельянов А.В., Тренделева Т.Е., Краснощекова О.И. Исследование взаимосвязи нижних и верхних дыхательных путей у больных аллергическим ринитом и бронхиальной астмой. Аллергология. 2001, № 3, с. 36.
  10. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт Медиа». 1998, 250 с.
  11. Becler K., Hakansson L., Rak S. Treatment of asthmatic patients with a cysteinyl leukotriene receptor-1 antagonist montelucast (Singulair), decreases the eosinophil survival-enhancing activity produced by peripheral blood mononuclear leukocytes in vitro. Allergy. 2002, v. 57, p. 1021-1028.
  12. Holgate S.T., Peters-Golden M., Panettieri R.A., Henderson W.R. Jr. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J. Allergy Clin. Immunol. 2003, v. 111, p. 18-34.
  13. Löfdahl C.G., Reiss T.F., Leff J.A. et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999, v. 319, p. 87-90.
  14. Malmstorm K., Rodriguez-Gomez G., Guerra J. et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast. Beclomethasone Study Group. Ann. Intern. Med. 1999, v. 130, p. 487-495.
  15. Riccioni G., Vecchia R.D., Castronuovo M. et al. Tapering dose of inhaled budesonide in subjects with mild-to-mod-erate persistent asthma treated with montelukast: a 16-week single-blind randomized study. Ann. Clin. Lab. Sci. 2005, v. 35, p. 285-289.
  16. Bisgaard H., Zielen S., Garcia-Garcia M.L. et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am. J. Respir. Crit. Care Med. 2005, v. 171, p. 315-322.
  17. Williams B., Noonan G., Reiss T.F. et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin. Exp. Allergy. 2001, v. 31, p. 845-854.
  18. Muijsers R.B., Noble S. Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age. Paediatr. Drugs. 2002, v. 4, p. 123-139.
  19. Phipatanakul W., Greene C., Downes S.J. et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann. Allergy Asthma Immunol. 2003, v. 91, p. 49-54.
  20. Joos S., Miksch A., Szecsenyi J. et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax. 2008, v. 63, p. 453-462.
  21. Global Strategy for Asthma Management and Prevention 2015. Global Initiative for Asthma. http://www.ginasthma.org.
  22. Bousquet J., Schunemann H.J., Samolinski B. et al. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. Allergy Clin. Immunol. 2012, v. 130, p. 1049-1062.
  23. Kamps A.W., van Ewjil B., Roorda R.J. et al. Poor inhalation technique even after inhalation instructions, in children with asthma. Pediatr. Pulm. 2000, v. 29, p. 39-42.
  24. Lenney J., Innes J., Cropmton G.K. Inappropriate inhaler use: assessment of use and preference of seven inhalation devices. Respir. Med. 2000, v. 94, p. 496-500.
  25. Juniper E.F., Bousquet J., Abetz L., Bateman E.D. GOAL Committee: Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the asthma control questionnaire. Respir. Med. 2006, v. 100, p. 616-621.
  26. Juniper E.F., O’Byrne P.M., Ferrie P.J. et al. Measuring asthma control. Clinic questionnaire or daily diary? Am. J. Respir. Crit. Care Med. 2000, v. 162, p. 1330-1334.
  27. Boulet L., Chanez P. Clinically Relevant Outcome Measures for New Therapies of Asthma Using Pharmaceutical and Biologic Agents. Curr. Opin. Allergy Clin. Immunol. 2015, v. 15, p. 213-219.
  28. Juniper E.F., O’Byrne P.M., Guyatt G.H. et al. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 1999, v. 14, p. 902-907.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2016



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies